Advanced

Fibrosis regression induced by intravenous gammaglobulin treatment

Amital, H; Rewald, E; Levy, Y; Bar-Dayan, Y; Manthorpe, Rolf LU ; Engervall, P; Sherer, Y; Langevitz, P and Shoenfeld, Y (2003) In Annals of the Rheumatic Diseases 62(2). p.175-177
Abstract
Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess... (More)
Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
62
issue
2
pages
175 - 177
publisher
British Medical Association
external identifiers
  • pmid:12525390
  • wos:000180577000015
  • scopus:0344341646
ISSN
1468-2060
DOI
10.1136/ard.62.2.175
language
English
LU publication?
yes
id
20c8710c-2dcc-4003-9a84-5f7bc058f3af (old id 891347)
date added to LUP
2008-01-10 09:13:31
date last changed
2018-01-07 09:10:33
@article{20c8710c-2dcc-4003-9a84-5f7bc058f3af,
  abstract     = {Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.},
  author       = {Amital, H and Rewald, E and Levy, Y and Bar-Dayan, Y and Manthorpe, Rolf and Engervall, P and Sherer, Y and Langevitz, P and Shoenfeld, Y},
  issn         = {1468-2060},
  language     = {eng},
  number       = {2},
  pages        = {175--177},
  publisher    = {British Medical Association},
  series       = {Annals of the Rheumatic Diseases},
  title        = {Fibrosis regression induced by intravenous gammaglobulin treatment},
  url          = {http://dx.doi.org/10.1136/ard.62.2.175},
  volume       = {62},
  year         = {2003},
}